I am honored to continue my tenure as Editor in Chief of Oncology Data Advisor in 2023. The last year was a thrill for me, as the post afforded me a front-row seat to lectures, panel discussions, and podcasts from some of the most respected names in our field. I can assure you that what we have planned for 2023 is even more ambitious with multiple interview series, long-form essays, and oncology-focused podcasts available nowhere else.

At the recent American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, Dr. Lisa Gudenkauf, an Applied Research Scientist at Moffitt Cancer Center, presented her team's research regarding the Functional Assessment of Cancer Therapy—Radionuclide Therapy (FACT-RNT), a novel patient-reported outcomes (PRO) measure for patients with prostate cancer. In this follow-up interview, Dr. Gudenkauf shares more about how the measure was developed, its importance for capturing the patient experience, and its future implementation into both clinical practice and trials.